海普瑞获批H1710临床试验
2月18日，海普瑞（002399/09989）发布公告，近日公司收到国家药品监督管理局核准签发的《药物临床试验批准通知书》，批准注射用H1710开展临床试验。
该药物的适应症为晚期实体瘤，属于化学药品1类，申请人为公司。审批结论表明，H1710符合药品注册的相关要求，允许在晚期实体瘤患者中进行临床试验。
H1710是公司自主研发的候选药物，具有全球开发及商业化权益。它是一种靶向乙酰肝素酶的全新化合物，表现出高效高选择性的乙酰肝素酶抑制活性，并在多种肿瘤动物模型中显示出显著的抑瘤作用。截至公告日，全球尚无同一分子机制的同类产品上市。需要注意的是，药品获得临床试验通知书后，仍需进行临床试验并取得相关数据，才能最终上市，存在一定的不确定性。
2024年前三季度，海普瑞实现收入40.69亿元，归母净利润7.8亿元。
（文章来源：财中社）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Most Discussed
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10